findmyKOL

Partow Kebriaei, MD

Enriched profile

Professor, Stem Cell Transplantation and Cellular Therapy; Clinic Medical Director · The University of Texas MD Anderson Cancer Center

ORCIDNPI
Region🇺🇸 Houston, TX · South Central · United StatesSpecialtyHematology / OncologyFocusAcute Lymphoblastic Leukemia research+4
Active KOLfindmyKOL typefindmyKOL type: our influence ranking, shown when you reveal the full profileLatest publication2026Online presenceverified 2026Payments2021–2025NIH fundingNone on fileWhy? →

Partow Kebriaei is Professor, Stem Cell Transplantation and Cellular Therapy; Clinic Medical Director at The University of Texas MD Anderson Cancer Center. OpenAlex indexes 1,134 publications with 27,445 citations (h-index 79); ClinicalTrials.gov lists 13 registered studies with this person as an investigator. By OpenAlex citation count, this profile ranks in the top 5% of Hematology / Oncology profiles in the findmyKOL directory.

Data verified 14 Aug 2026

Overview

Updated 27 Aug 2026

Partow Kebriaei, MD, is Professor, Stem Cell Transplantation and Cellular Therapy at The University of Texas MD Anderson Cancer Center, Department of Stem Cell Transplantation and Cellular Therapy, Houston, TX. The public record shows 1,134 publications with 27,445 citations (h-index 79), centered on Acute Lymphoblastic Leukemia research, Hematopoietic Stem Cell Transplantation, CAR-T cell therapy research. It also documents an investigator role on 13 registered clinical trials, industry payments reported by 11 companies.

  • Most recent indexed publication: 2026 · Bone marrow transplantation
  • Top research focus: Acute Lymphoblastic Leukemia research
  • 13 registered trials on ClinicalTrials.gov
  • Open Payments reporting from 11 companies

Generated from the cited public record · current as of 27 Aug 2026. Every fact links its source below.

Indications focus

from trials led + research topics
Leukemia (AML/ALL/CML/CLL)9 trialsLymphoma8 trialsPrecursor Cell Lymphoblastic Leukemia-Lymphoma5 trialsMultiple Myeloma2 trialsLymphoma, B-Cell2 trialsLymphoma, Non-Hodgkin2 trialsLeukemia, Lymphocytic, Chronic, B-Cell2 trialsHodgkin Disease2 trialsLeukemia, Lymphoid2 trialsMDS / MPN1 trialLeukemia, Myeloid, Acute1 trialNeoplasm, Residual1 trialLeukemia, Biphenotypic, Acute1 trialRetroviridae Infections1 trialLymphoma, Large B-Cell, Diffuse1 trial

Research focus

OpenAlex concept fingerprint
Acute Lymphoblastic Leukemia researchHematopoietic Stem Cell TransplantationCAR-T cell therapy researchAcute Myeloid Leukemia ResearchChronic Myeloid Leukemia Treatments

Drugs & molecules

across trials, industry payments and publications
Besponsageneric · Inotuzumab ozogamicinClinical trialsIndustry payments3Publications3Tecartusgeneric · Brexucabtagene autoleucelClinical trialsIndustry payments3PublicationsDefiteliogeneric · DefibrotideClinical trialsIndustry payments2Publications

Works with

trial sponsors and companies reporting payments
National Marrow Donor ProgramClinical trialsIndustry payments20M.D. Anderson Cancer CenterClinical trials13Industry paymentsJazz Pharmaceuticals Inc.Clinical trialsIndustry payments3

Scholarship

indexed output and impact (OpenAlex)
View publications ↓
1,134publications

Distinct works indexed by OpenAlex, matched via ORCID; 28 in PubMed.

27,445citations

Total citations across indexed works.

79h-index

Hirsch index (OpenAlex). i10-index 321.

Clinical & industry

trials, payments and federal funding
13clinical trials

Investigator role on registered studies.

View trials
11companies · 2021–2025

Companies reporting payments to CMS. Facts, not judgments.

View payments
0NIH grants

Federally funded research awards.

Contact

The practice address and phone this provider lists in the federal NPPES (CMS) registry.

Practice address

Telephone

Practice address and telephone from the federal NPPES registry.

Sign in to view contact details →

Clinical trials

Updated 27 Aug 2026

Listed as an investigator on 13 registered studies on ClinicalTrials.gov. The most recent:

Industry payments

Updated 27 Aug 2026

11 companies reported payments to CMS in program years 2021–2025. These are public disclosures, not judgments. The latest:

Medicare prescribing footprint (2024)

The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.

  • Anti-infectives

    70.3%
    Azole Antifungal22%
    Posaconazole100%
    Part D<11 patients
    Herpesvirus Nucleoside Analog DNA Polymerase Inhibitor19.8%
    Valacyclovir100%
    Part D<11 patients
  • Metabolism & gastrointestinal

    15.4%
    Proton pump inhibitor15.4%
    Pantoprazole Sodium100%
    Part D<11 patients
  • Cancer & immunology

    14.3%
    BCL-2 Inhibitor14.3%
    Venclexta100%
    Part D<11 patients
Where care is delivered (Part B)100% facility · 0% office

Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.

NIH funding

We didn't find any NIH-funded research awards for this person in NIH RePORTER. Why? →

Congress activity

Updated 27 Aug 2026

202 congress contributions (2006–2025) across ASCO, ASH, ASTRO, ESMO per OpenAlex. The most recent:

Publications

Updated 27 Aug 2026

Their five most recent publications, matched to their ORCID record and linked to PubMed.

Network

Updated 27 Aug 2026

The people this person publishes with most, by number of co-authored papers. Names link to their own profile when we have one.

Richard E. Champlin625Elizabeth J. Shpall562Uday Popat441

Online presence

Updated 27 Aug 2026

This person's own public accounts first, then places where others mention them. Two different things, listed separately.

Owned accounts

public accounts run by this person
  • Doximity

    doximity.com/pub/partow-kebriaei-md

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →doximity.com

Mentions by others

where others cite or feature them
  • ResearchGate

    researchgate.net/scientific-contributions/Partow-Kebriaei-38513144

    provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →researchgate.net

We list an account only when the public record ties it to this person. verified means we've confirmed the match in more than one place; provisional means it looks right but we're still confirming.

Background & recognition

Updated 27 Aug 2026

Credentials, appointments and honors, newest first, each linked to the public source it came from.

Education

degrees and training on record
  • Board Certified

    Hematology

    2004
    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →faculty.mdanderson.org
  • Board Certified

    Medical Oncology

    2003
    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →faculty.mdanderson.org
  • Board Certified

    Internal Medicine

    2001
    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →faculty.mdanderson.org
  • M.D.

    University of Texas Health Science Center, Houston

    1997
    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →faculty.mdanderson.org
  • B.S. in Biology

    Yale University

    1993
    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →faculty.mdanderson.org

Editorial & leadership roles

journal and society appointments
1 more role behind the reveal.Reveal →

Awards & honors

honors on the public record
1 more award behind the reveal.Reveal →

Media & interviews

press, podcasts and appearances
  • VJHemOnc speaker profile

    multiple video interviews on ALL/AML transplant topics (Video Journal of Hematology and Hematological Oncology)

    provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →vjhemonc.com
  • OncLive author/contributor

    video interviews and articles on stem cell transplant, CAR T-cells, Iomab-B trial in AML

    provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →onclive.com
  • Targeted Oncology contributing author

    interviews/articles on immunotherapy and transplant in ALL

    provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →targetedonc.com

Every item links to where we found it. verified means we've confirmed it in more than one place; provisional means we found it and are still confirming.

Similar KOLs

Other experts from the same institution or the same specialty.